Aminopenicillin drugs kill bacteria by inhibiting the synthesis of the bacterial cell wall. Aminopenicillin drugs are bactericidal beta-lactam antibiotics. There exists chemical similarity between aminopenicillin drugs and penicillin. However, aminopenicillin drugs have a broader spectrum of activity than penicillin. Aminopenicillin drugs can be administered orally, as acid hydrolysis does not deactivate these drugs. However, aminopenicillin drugs are sometimes given along with beta-lactamase inhibitors, as these drugs are susceptible to hydrolysis by beta-lactamase. Aminopenicillin drugs are effective against most gram-negative bacteria such as H. influenza and E. coli as well as gram-positive bacteria. They are employed to treat infections of the lower and upper respiratory tract, skin infections, endocarditis, and urinary tract infections.
Increasing prevalence of bacterial infections all over the world drives the global aminopenicillin drugs market. The increasing pool of patients suffering from bacterial infections and high cost of new drugs are factors likely to boost the market remarkably in the next few years. The rising level of awareness, better treatment facilities, continued launches of effective drugs, and presence of favorable reimbursement policies for high-cost treatments are also expected to drive the global aminopenicillin drugs market during the forecast period. However, the number of key players operating in the market is less, which is projected to restrain the market during the forecast period. There exists an opportunity for new entrants to enter the global aminopenicillin drugs market. The geriatric population is more prone to infections due to low immunity levels. Infections, especially bacterial infections, are becoming increasingly common among the elderly people. According to the World Health Organization (WHO), among every 100 hospitalized patients at any given time, 10 in developing countries and seven in developed countries acquire at least one health care-associated infection.
The global aminopenicillin drugs market can be categorized based on product, infection type, distribution channel, and region. Based on product, the market can be classified into branded drugs and generic drugs. In terms of infection type, the market can be categorized into bone infection, skin infection, ENT infections, gastrointestinal infection, surgical site infections, bloodstream infections, ventilator-associated pneumonia, and urinary tract infections. In terms of distribution channel, the market can be divided into online pharmacies, retail pharmacies, and hospital pharmacies. The hospital pharmacies segment held the leading market share in 2016, owing to increased hospital visits and high prevalence of hospital-acquired infections across the world. The online pharmacies segment is anticipated to expand at a rapid pace during the forecast period, owing to increased awareness about online pharmacies in developed as well as developing countries.
Geographically, the global aminopenicillin drugs market can be divided into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America held a major market share in 2016, due to presence of a large number of multi-drug resistant bacteria and high prevalence of various bacterial infections in the region. This region also has large geriatric population that is more prone to different infections led by lowered level of immunity. Hence, the elderly people require use of various aminopenicillin drugs. This, in turn, augments the aminopenicillin drugs market North America. Europe held the second-largest market share in 2016, due to technological advancements and rise in research and development of aminopenicillin drugs in the region. The aminopenicillin drugs market in Asia Pacific is likely to expand rapidly during the forecast period. Growth of the market in the region is attributable to developing infrastructure, growing awareness, and increasing purchasing power of the people in the region. The market in Middle East & Africa and Latin America is anticipated to expand during the forecast period, due to rising prevalence of bacterial infections in these regions.
Key players operating in the global aminopenicillin drugs market include GlaxoSmithKline plc and Pfizer Inc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.